Disciform Scars from Wet AMD: Long-Term Care
Understanding Disciform Scars
A disciform scar is a patch of dense fibrous tissue that replaces the normal layers of the retina. It forms as the end result of choroidal neovascularization (CNV), which is the growth of abnormal blood vessels beneath the retina. These fragile vessels leak fluid and blood into the surrounding tissue. Over time, the body responds by creating scar tissue that replaces the damaged retinal cells. This damage cannot be undone with current treatments.
The scar typically measures 4 to 8 millimeters in diameter and sits in the macula, the part of the retina responsible for sharp central vision. Once the scar is fully formed, the photoreceptors (the light-sensing cells) and the retinal pigment epithelium (a supportive layer beneath the retina) in that area are destroyed. This creates an irreversible blind spot in the center of vision known as a central scotoma.
The process begins when vascular endothelial growth factor (VEGF), a protein that signals new blood vessel growth, is overproduced in the eye. This triggers the growth of abnormal blood vessels under the retina. These new vessels are weak and leaky. They allow fluid, blood, and fatty deposits called lipids to seep into the retinal layers.
Without treatment, this leaking and bleeding triggers a wound-healing response. The abnormal blood vessels are gradually replaced by thick scar tissue over roughly 6 to 18 months. Once this fibrotic process is complete, the disciform scar is considered metabolically inactive. However, in some cases, new abnormal vessel growth can restart at the edges of the scar.
Wet AMD accounts for approximately 10% of all AMD cases, yet it is responsible for 60 to 90% of severe vision loss and legal blindness caused by the disease (AAO, 2024). A disciform scar represents a point where central vision loss becomes irreversible. For this reason, preventing scar formation through early treatment is one of the most important goals in managing wet AMD.
Who Is Affected and Risk Factors
In 2019, an estimated 19.8 million Americans aged 40 and older had some form of AMD, accounting for 12.6% of the population. Among these, approximately 1.49 million had vision-threatening late-stage AMD, which includes both wet AMD and geographic atrophy (CDC VEHSS, 2019). In 2021, Medicare data showed that wet AMD affected 2.14% of beneficiaries aged 65 and older (PubMed, 2025).
The risk of developing wet AMD increases significantly with age. Prevalence rises from approximately 2% in adults aged 50 to 59 to over 15% in white women over 80 (NEI, 2024). White individuals are at higher risk compared to other racial and ethnic groups. Women are also affected more often than men.
Family history plays a major role. Two gene variants, CFH and ARMS2, account for 50 to 75% of the genetic risk for AMD (NEI, 2024). Having a close relative with AMD significantly raises a person's own risk.
Smoking is one of the strongest modifiable risk factors. Risk increases in a dose-dependent manner. This means the more a person smokes and the longer they smoke, the higher the risk. Cardiovascular disease, high blood pressure, and obesity also contribute to increased risk.
Patients with large soft drusen (yellow deposits under the retina) or pigmentary changes in the macula are at the highest risk for progressing from dry AMD to wet AMD. Those who have wet AMD in one eye face a 4 to 12% annual risk of developing it in the other eye (AAO, 2024). Without early and consistent treatment, wet AMD can progress to disciform scarring within months.
Signs and Symptoms
The earliest symptoms of wet AMD often involve changes in central vision. These may include straight lines appearing wavy or bent, a condition called metamorphopsia. Some people notice a blurry or dark spot in the center of their vision. Difficulty reading, recognizing faces, or performing detailed tasks can also signal a problem.
These symptoms can appear suddenly. Any acute change in central vision warrants immediate evaluation by a retina specialist or an emergency room visit. Early treatment can make a significant difference in preserving vision.
Once a disciform scar has formed, central vision is typically severely reduced, often to 20/200 or worse. Patients usually have a fixed, dense blind spot in the center of their visual field. Peripheral vision and side vision generally remain intact. This allows some degree of independent movement and daily function.
Although a mature disciform scar is generally inactive, reactivation can occur at the edges of the scar. Warning signs of reactivation include the scar appearing to enlarge on imaging, new lipid deposits around the scar, fresh bleeding beneath the retina, or a noticeable decline in vision near the affected area. Any of these changes require prompt evaluation by a retina specialist.
Diagnosis and Testing
A retina specialist will perform a dilated eye exam to examine the macula and surrounding retina in detail. During this exam, the specialist uses magnifying lenses and bright lights to look for signs of fluid, blood, scarring, or abnormal blood vessel growth. A visual acuity test measures how well a patient can see at various distances.
Optical coherence tomography (OCT) is a noninvasive imaging scan that creates detailed cross-sectional pictures of the retina. OCT can reveal fluid under or within the retina, thickening or thinning of retinal layers, and the presence of fibrotic scar tissue. This test is critical for monitoring disease activity and determining whether treatment is working.
In fluorescein angiography, a special dye is injected into a vein in the arm. As the dye travels through the blood vessels in the retina, a camera captures images that show areas of leaking or abnormal vessels. This test helps confirm the presence of CNV and guides treatment decisions.
Indocyanine green angiography (ICGA) uses a different dye that highlights deeper blood vessels beneath the retina, particularly in the choroid layer. ICGA is especially useful for detecting polypoidal choroidal vasculopathy (PCV), a variant of wet AMD. PCV involves balloon-like swellings on the abnormal blood vessels. It is associated with a higher rate of scar reactivation and may require a different treatment approach.
Treatment Options
The primary goal of treating wet AMD is to stop abnormal blood vessel growth before a disciform scar can form. Anti-VEGF medications block the protein that drives this abnormal growth. These drugs are injected directly into the eye in a procedure called an intravitreal injection.
FDA-approved anti-VEGF options include:
- Lucentis (ranibizumab), typically given every 4 weeks
- Eylea (aflibercept), given every 4 to 8 weeks after an initial loading phase
- Eylea HD (high-dose aflibercept), which may extend dosing to every 8 to 16 weeks after loading
- Vabysmo (faricimab), a bispecific antibody given every 4 to 16 weeks
- Beovu (brolucizumab), given every 8 to 12 weeks, though it carries a risk of retinal vasculitis
- Avastin (bevacizumab), used off-label for eye conditions and given every 4 to 6 weeks. Avastin is FDA-approved for cancer treatment but is commonly compounded for retinal use.
Retina specialists use several treatment strategies depending on how the disease responds. Monthly injection schedules provide the most consistent control. A treat-and-extend approach gradually lengthens the time between injections as long as the disease stays stable. Pro re nata (PRN, or as-needed) dosing involves treating only when signs of active disease return on imaging.
Early and consistent treatment is essential. Delays or gaps in treatment increase the risk of the disease progressing to irreversible scarring.
Once a disciform scar is fully formed, anti-VEGF therapy is generally stopped because the scar tissue has already replaced the functional retina. Visual acuity at this stage is typically below 20/200. Further injections cannot reverse the damage.
However, ongoing monitoring remains important. Retina specialists will continue to perform periodic OCT scans and clinical examinations to check for reactivation at the edges of the scar.
In select cases, particularly those with polypoidal features, reactivation of abnormal vessel growth can occur at the margins of a disciform scar. When this happens, a retina specialist may use focal laser photocoagulation (a targeted laser treatment) guided by ICGA imaging. Anti-VEGF injections may also be restarted if active fluid or bleeding is detected.
What to Expect
A disciform scar causes irreversible loss of central vision. Most patients with a fully formed scar have visual acuity of 20/200 or worse in the affected eye. The central blind spot makes it very difficult to read, drive, or recognize faces using that eye alone.
Peripheral vision is typically preserved. This allows patients to navigate spaces, maintain awareness of their surroundings, and perform many daily activities with appropriate support.
Patients with wet AMD in one eye face a 4 to 12% annual risk of developing the disease in their other eye (AAO, 2024). For this reason, regular monitoring of the unaffected eye is essential. Many retina specialists recommend daily use of an Amsler grid, a simple printed chart of straight lines used to detect early distortion. Any new waviness or missing areas on the grid should prompt an immediate appointment.
Even after active treatment stops for a scarred eye, retina specialists typically recommend follow-up visits every 3 to 6 months. These visits allow the specialist to monitor for scar reactivation, check the health of the other eye, and update the care plan as new treatments become available.
Living with a Disciform Scar
Low vision rehabilitation is a structured program that helps patients make the most of their remaining vision. Specialists in low vision can prescribe magnifying devices, specialized lighting, and electronic aids that enlarge text and images. These tools can make reading, cooking, and other tasks more manageable despite central vision loss.
Many patients find that training with these devices significantly improves their confidence and independence in daily life.
Living with significant vision loss can affect emotional well-being. Feelings of frustration, grief, and anxiety are common and understandable. Support groups, counseling, and community resources for people with vision loss can provide valuable help.
Maintaining a healthy lifestyle also remains important. Eating a diet rich in leafy green vegetables, exercising regularly, avoiding smoking, and managing blood pressure and cholesterol may help protect the remaining vision in the other eye.
Researchers are actively working on new ways to prevent and manage wet AMD progression. Longer-acting anti-VEGF medications aim to reduce the number of injections patients need. Some newer agents maintain disease control with injections every 10 to 16 weeks. Biosimilar medications are expanding access to treatment.
Gene therapy and sustained-release drug delivery systems are under investigation. These approaches could provide more durable disease control and further reduce the risk of progression to disciform scarring. While these treatments are still in clinical trials, they represent a promising direction for future care.
When to See a Retina Specialist
Certain vision changes require same-day evaluation. See a retina specialist or go to the emergency room immediately if you experience any of the following:
- Sudden loss of central vision in one or both eyes
- Straight lines suddenly appearing wavy or distorted
- A new dark or blurry spot in the center of your vision
- A sudden increase in floaters or flashes of light
- A shadow or curtain appearing over part of your vision
If you have been diagnosed with any form of AMD, regular visits to a retina specialist are important even when your vision feels stable. Many changes in wet AMD occur before a patient notices symptoms. Catching these changes early through imaging and examination gives the best chance of preserving vision.
Adults over age 50, particularly those with a family history of AMD, a history of smoking, or cardiovascular disease, should have regular comprehensive eye exams. If drusen or pigmentary changes are found, a retina specialist can establish a monitoring schedule and recommend steps to reduce the risk of progression.
Questions and Answers
A disciform scar cannot be reversed, removed, or repaired with current treatments. The scar represents irreversible replacement of functional retinal tissue with fibrous tissue. No medication, laser, or surgery available today can restore the photoreceptors or retinal pigment epithelium destroyed by the scarring process. Treatment efforts focus on preventing scar formation in the first place through timely anti-VEGF therapy.
Ongoing monitoring serves two important purposes. First, abnormal blood vessel growth can reactivate at the edges of a disciform scar, particularly in patients with polypoidal choroidal vasculopathy. Detecting this early allows targeted treatment that may prevent the scar from expanding. Second, patients with a disciform scar in one eye are at significant risk of developing wet AMD in their other eye. Regular visits allow the retina specialist to catch any new disease activity in the fellow eye as early as possible.
Protecting the other eye involves a combination of regular monitoring and healthy lifestyle choices. Use an Amsler grid daily to check for new distortion or blind spots. Report any changes to a retina specialist right away. Avoid smoking, eat a balanced diet with plenty of leafy greens and fish, maintain a healthy weight, and manage blood pressure and cholesterol. A retina specialist may also recommend specific nutritional supplements based on formulations studied in the Age-Related Eye Disease Study (AREDS2).
Yes, these are two different forms of advanced AMD. A disciform scar results from wet AMD, where abnormal blood vessels leak and bleed, eventually forming scar tissue. Geographic atrophy is a form of advanced dry AMD, where retinal cells slowly waste away over time without abnormal blood vessel growth. Both cause irreversible vision loss, but they involve different disease processes. Geographic atrophy may be treated with complement inhibitors such as Syfovre (pegcetacoplan), a C3 inhibitor, or Izervay (avacincaptad pegol), a C5 inhibitor. These medications are not used for wet AMD or disciform scars. These complement inhibitor treatments are specifically for geographic atrophy associated with dry AMD and are different from wet AMD treatments.
The AREDS2 formula includes vitamins C and E, zinc, copper, lutein, and zeaxanthin. It has been shown to reduce the risk of progression from intermediate dry AMD to advanced AMD (NEI, 2024). Supplements do not treat existing wet AMD or reverse a disciform scar. However, they may help slow the overall progression of the disease. A retina specialist can advise whether AREDS2 supplements are appropriate based on the specific stage and type of AMD present.